Irinotecan-Induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms

Molecular Cancer Therapeutics

Volumn 15, Issue 6, 2016, Pages 1376-1386

  Wardill, Hannah R ^a   Gibson, Rachel J ^a,b   Van Sebille, Ysabella Z A ^a   Secombe, Kate R ^a   Coller, Janet K ^a   White, Imogen A ^a   Manavis, Jim ^a   Hutchinson, Mark R ^a,c   Staikopoulos, Vasiliki ^a   Logan, Richard M ^a   Bowen, Joanne M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c and the Centre for Nanoscale BioPhotonics The University of Adelaide 5005South Australia Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; TOLL LIKE RECEPTOR 4; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; FEMALE; GASTROINTESTINAL PAIN; GASTROINTESTINAL TOXICITY; GENE DELETION; GLIA CELL; HISTOPATHOLOGY; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LUMBAR SPINAL CORD; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIUM; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DNA SEQUENCE; DRUG EFFECTS; FECES; GASTROINTESTINAL DISEASE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIOLOGY; PAIN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BACTERIA; CAMPTOTHECIN; FECES; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; GENE DELETION; GENE EXPRESSION REGULATION; MICE; MICE, INBRED BALB C; PAIN; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84971578038     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0990     Document Type: Article

References (48)

1. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120:1453-61.
2. Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. PharmacoEconomics 2013;31:753-66.
3. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-84.
4. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-59.
5. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 2008; 7:1919-25.
6. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 2009; 90:489-99.
7. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med 2009;234:430-41.
8. Wardill HR, Gibson RJ, Logan RM, Bowen JM. TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer 2014;135:2483-92.
9. Wardill HR, Van Sebille YZ, Mander KA, Gibson RJ, Logan RM, Bowen JM, et al. Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treat Rev 2015;41:122-8.
10. Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013;21:2075-83.
11. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005;288:G1055-65.
12. De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine 2015;74:181-9.
13. Jacobsen JH, Watkins LR, Hutchinson MR. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. Int Rev Neurobiol 2014;118:129-63.
14. Bowen JM, Coller J, Hutchinson M, Gibson RJ. Expression of TLRs in the rat intestine following chemotherapy for cancer. Brain Behaviour Immunity 2012;26:S27-S.
15. Gibson RJ, Coller JK, Wardill HR, Hutchinson M, Smid SD, Bowen JM. Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Support Care Cancer 2016;24:2251-8.
16. Aprile G, Ramoni M, Keefe D, Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 2008;112:284-92.
17. Phipps S, Lam CE, Kaiko GE, Foo SY, Collison A, Mattes J, et al. Toll/IL-1 signaling is critical for house dust mite-specific helper T cell type 2 and type 17 [corrected] responses. Am J Respir Crit Care Med 2009;179:883-93.
18. Gibson RJ, Bowen JM, Alvarez E, Finnie J, Keefe DM. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007;53:360-9.
19. Sotocinal SG, Sorge RE, Zaloum A, Tuttle AH, Martin LJ, Wieskopf JS, et al. The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol Pain 2011;7:55.
20. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
21. Zhang J, Kobert K, Flouri T, Stamatakis A. PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 2014;30:614-20.
22. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010;7:335-6.
23. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010;26:2460-1.
24. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011;27: 2194-200.
25. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996;126:2519-30.
26. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000;47:632-7.
27. Helps SC, Thornton E, Kleinig TJ, Manavis J, Vink R. Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol 2012; 20:82-90.
28. Bland M. The analysis of cross-tabulation. An introduction to medical statistics . 3rd ed. New York: Oxford University Press; 2005.
29. Stringer AM, Al-Dasooqi N, Bowen JM, Tan TH, Radzuan M, Logan RM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013;21:1843-52.
30. Hufeldt MR, Nielsen DS, Vogensen FK, Midtvedt T, Hansen AK. Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors. Comp Med 2010;60:336-47.
31. Kuehbacher T, Rehman A, Lepage P, Hellmig S, Folsch UR, Schreiber S, et al. Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. J Med Microbiol 2008;57:1569-76.
32. Pedroso SH, Vieira AT, Bastos RW, Oliveira JS, Cartelle CT, Arantes RE, et al. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 2015;161:1950-60.
33. Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I, et al. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of beta-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol 2011;67:201-13.
34. Gibson DL, Ma C, Bergstrom KS, Huang JT, Man C, Vallance BA. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol 2008;10:618-31.
35. Frank M, Hennenberg EM, Eyking A, Runzi M, Gerken G, Scott P, et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 2015;194:1983-95.
36. Afrazi A, Branca MF, Sodhi CP, Good M, Yamaguchi Y, Egan CE, et al. Tolllike receptor 4-mediated endoplasmic reticulum stress in intestinal crypts induces necrotizing enterocolitis. J Biol Chem 2014;289:9584-99.
37. Deng M, Scott MJ, Loughran P, Gibson G, Sodhi C, Watkins S, et al. Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol 2013;190:5152-60.
38. Pathak SK, Basu S, Bhattacharyya A, Pathak S, Banerjee A, Basu J, et al. TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from macrophages. J Immunol 2006;177:7950-8.
39. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-103.
40. Shoenfelt J, Mitkus RJ, Zeisler R, Spatz RO, Powell J, Fenton MJ, et al. Involvement of TLR2 and TLR4 in inflammatory immune responses induced by fine and coarse ambient air particulate matter. J Leukoc Biol 2009;86:303-12.
41. Holmes D. Trying to unravel the mysteries of chemobrain. Lancet Neurol 2013;12:533-4.
42. Ji XT, Qian NS, Zhang T, Li JM, Li XK, Wang P, et al. Spinal astrocytic activation contributes to mechanical allodynia in a rat chemotherapyinduced neuropathic pain model. PLoS One 2013;8:e60733.
43. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
44. Huang HY, Zhang ZJ, Cao CB, Wang N, Liu FF, Peng JQ, et al. The TLR4/NFkappaB signaling pathway mediates the growth of colon cancer. Eur Rev Med Pharmacol Sci 2014;18:3834-43.
45. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010;29:92.
46. Jain S, Suklabaidya S, Das B, Raghav SK, Batra SK, Senapati S. TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. Prostate 2015;75:1020-33.
47. Farzi A, Halicka J, Mayerhofer R, Frohlich EE, Tatzl E, Holzer P. Toll-like receptor 4 contributes to the inhibitory effect of morphine on colonic motility in vitro and in vivo. Sci Rep 2015;5:9499.
48. Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 2012;143:1006-16e4.